dual her1/her2 inhibitors (Bristol-Myers Squibb)

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug Namedual her1/her2 inhibitors (Bristol-Myers Squibb)

Drug Alias Namedual erbB1/erbB2 inhibitors (Bristol-Myers Squibb)dual epidermal growth factor receptor modulators (BMS)dual erbB1/erbB2 inhibitors (BMS)BMS-690858BMS-595338

ClassificationSmall molecules

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsAnticancer protein kinase inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryWorld

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBristol-Myers Kk

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBristol-Myers Kk

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A